Policies
15 Mandatory and 102 Recommended Standards to be Revised in 2023
The NMPA issued the final document of “2023 Medical Device Industry Standards Revisions Plan” on May 24, two weeks after the release of draft version. 15 mandatory and 102 recommended standards will be revised or established.
The 15 industry mandatory standards impact the devices such as blood pressure sensor, bone joint implant devices, Bone joint implant device Metal bone plate, laser treatment machine, cardiopulmonary diversion system, hemoperfusion equipment, dentistry hydrostatine device, etc. For the full list please visit HERE
Guidelines & Standards
Intracranial Coil and Stent Retriever Guidelines Ask Your Feedback
The NMPA issued a notice titled “Information Collection from Enterprises and Institutions Related to the Preparation of the Guideline for Intracranial Coils and Guideline for Stent Retrievers” on May 17, 2023. The deadline is May 31, 2023.
According to Chinese Circulation Journal published in 2022, two out of every five deaths in China were due to cardiovascular disease (CVD). It is estimated that about 330 million patients suffer from CVD in China. For more information please click HERE
Recombinant Collagen Raw Materials and Wound Dressings Guidelines Published
The NMPA issued “Guideline on Recombinant Humanized Collagen Raw Materials” and “Guideline on Recombinant Collagen Wound Dressings” on May 23, 2023.
The 54-page collagen raw materials guideline stipulates the four vital points for registration review as material performance study, material Immunological safety, biological risks, and stability and direct contact container study.
The Guideline on Recombinant Collagen Wound Dressings confirms that the collagen wound dressings are Class II device. When classified into subcategories of -01 wound dressing, -04 gel dressing and -08 liquid, paste dressing, they can be exempted from clinical trial. For more highlights from the guidelines please visit HERE
Innovation Approvals
Imported Intravascular Imaging Equipment Gains Innovation Approval
On May 16, 2023, the NMPA granted innovation approval to Conavi Medical Inc., from Canada, for its intravascular imaging system. It is the fourth imported innovative device approved by the NMPA so far in 2023, after Medtronic, Alcon, and Ubiosis’ approvals.
For NMPA’s opinion on the intravascular imaging system, please click HERE
About China Med Device, LLC
China Med Device, LLC (www.ChinaMedDevice.com) provides regulatory and commercialization turnkey solutions for medical device, IVD, CDx and combination products in China. As a qualified NMPA legal agent with offices in Boston, Beijing and Hainan, we can represent manufacturers for the complete product life cycle without their need to create a local entity in China. Our regulatory services include strategy, registration, type testing, product technical requirement (PTR), clinical evaluation report (CER), clinical trial, GMP and post-market surveillance. Our commercialization services include market research, reimbursement, partnership strategy and distribution qualification.
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoAiStream. Web3 Data Intelligence. Knowledge Amplified. Access Here.
- Minting the Future w Adryenn Ashley. Access Here.
- Buy and Sell Shares in PRE-IPO Companies with PREIPO®. Access Here.
- Source: https://chinameddevice.com/nmpa-device-may-2023/
